Oncology
and Radiotherapy ©
17 (10) 2023: 744-750 • REVIEW

Enhancing cervical cancer survival through innovative radiotherapy interventions: a narrative review

Aastha Sharma[1], Dr. Maha Gasmi[2], Dr. Kirti Amresh Gautam[3], Diksha Melkani[4]

[1]Department of basic and applied science, School of engineering and science, University, GD Goenka University Gurugram, India

[2] Higher Institute of Sport and Physical Education of Ksar Said University of Manouba, Tunisia.

[3] Department of basics and applied science, School of engineering and science, GD Goenka University Gurugram, India

[4] Department of Life Science, Graphic era deemed university, Dehradun, India

ABSTRACT

Due to improvements in early identification and diverse therapies, cervical cancer, a serious global health issue and a leading cause of cancer-related death has witnessed a rise in survival rates. By administering precise dosages to tumour tissues while limiting harm to healthy structures, radiotherapy is a key component in the care of cervical cancer. Proton therapy, IMRT, and IGRT are a few examples of cutting-edge radiation methods that have completely changed how treatments are delivered while also reducing side effects and improving tumour control. Patients' results are further improved by combination treatments, such as concomitant chemoradiotherapy. Despite these developments, issues with cost, access, and long-term data validation continue. It is crucial to comprehend the concepts and operating processes of radiobiology that underlie these therapies. The future holds hope for improving cervical cancer patient's quality of life and survival rates through the combination of cutting-edge technologies, individualized treatment programs, and patient-centred care. Collaboration is essential to ensuring equal access and successful implementation of these cutting-edge medicines into clinical practice, though.

Key words: cervical cancer, radiotherapy, external beam radiotherapy, brachytherapy, Intensity-Modulated Radiation Therapy (IMRT), Oxygen Enhancement Ratio (OER), Image-Guided Radiotherapy (IGRT), proton therapy, Volumetric Intensity-Modulated Arc Radiation Treatment (VMAT).

Address for correspondence:
Diksha Melkani
Department of Life Science, Graphic Era deemed university, Dehradun, India. Email: dikshamelkani072@gmail.com

Received: 05 September, 2023, Manuscript No.: OAR-23-116896
Editor Assigned: 07 September, 2023, PreQC No.: OAR-23-116896 (PQ)
Reviewed: 30 September, 2023, QC No.: OAR-23-116896 (Q)
Revised: 07 October, 2023, Manuscript OAR-23-116896 (R)
Published: 14 October, 2023, Invoice No. GP-OAR-23-116896

INTRODUCTION

Cervical cancer is a significant global health concern, ranking as the fourth most common cancer among women worldwide [1]. Despite advances in early detection and treatment modalities, it remains a leading cause of cancer-related mortality, particularly in low- and middle-income countries where resources for cancer care are limited [2]. Radiotherapy, as a cornerstone of cervical cancer management, has demonstrated substantial potential to improve survival rates and quality of life for affected individuals.

Cervical cancer survival rates have shown positive trends over the years, largely attributed to the implementation of screening programs and advancements in multidisciplinary treatment approaches [3]. Radiotherapy, in particular, has proven to be an integral component of curative and palliative care strategies for cervical cancer patients. By delivering targeted doses of ionizing radiation to cancerous tissues, radiotherapy aims to eliminate or control tumor growth while minimizing damage to surrounding healthy tissues [4].

The introduction of innovative radiotherapy techniques has revolutionized cervical cancer management. External beam radiotherapy, brachytherapy, and IMRT are among the evolving approaches that have exhibited improved treatment outcomes and reduced treatment-related toxicities [5]. These interventions have contributed to enhanced local tumor control and increased survival rates.

Additionally, radiotherapy's role extends beyond primary treatment. It plays a crucial role in the management of recurrent and metastatic cervical cancer, offering palliative relief and potentially extending overall survival [6]. Combining radiotherapy with chemotherapy or targeted therapies has demonstrated synergistic effects, further underscoring its potential to improve patient outcomes [7].

The study enrolled 200 patients with advanced NSCLC who were randomly assigned to receive either radiotherapy alone, targeted therapy alone, or a combination of both treatments [8].

Despite these promising developments, challenges persist. Disparities in access to radiotherapy services, particularly in resource-constrained regions, hinder the realization of its full potential [9]. Moreover, optimizing radiotherapy protocols, dose fractionation, and treatment planning to individual patient characteristics remains an ongoing research frontier. The interplay between tumor microenvironment, radiation-induced immune responses, and treatment outcomes adds complexity to the understanding of cervical cancer radiotherapy [10]. According to the study, cancer patients who had both radiation and targeted treatment benefited significantly [11]. In contrast to individuals getting either therapy alone, it is noteworthy that the group receiving both treatments demonstrated a much greater tumor response rate as seen by the reduced tumor size and imaging data. Along with better overall survival rates and a noticeable extension in median overall survival, the combination treatment group also reported prolonged progression-free survival, which denotes a longer duration without disease progression. Importantly, as compared to single-agent therapies, this combination therapy strategy was well-tolerated by patients and did not increase severe adverse effects. The potential for a more efficient and bearable therapeutic approach in the battle against cancer is highlighted by these findings.

Given the multifaceted character of cervical cancer survival in conjunction with radiotherapy, this exhaustive review has the primary objective of delving into the contemporary panorama of inventive radiotherapy interventions within the realm of cervical cancer management. Through the meticulous examination of recent research discoveries, clinical trials, and technological strides, this review aims to underscore the capacity of radiotherapy to augment both cervical cancer survival rates and the quality of life for affected individuals [12]. Moreover, it aims to discern lacunae in existing knowledge, address challenges, and outline prospective research directions that may propel enhancements in treatment effectiveness, accessibility, and ultimately, patient outcomes.

In recognition of the intricate factors influencing cervical cancer survival and radiotherapy, this narrative review intends to investigate contemporary innovative radiotherapy approaches within the sphere of cervical cancer management. Through an examination of recent research discoveries, clinical trials, and technological advancements, this review endeavours to underscore radiotherapy's potential for augmenting both survival rates and the overall quality of life for cervical cancer patients. Additionally, it seeks to pinpoint areas of knowledge deficiency, confront challenges, and propose avenues for future research, with the ultimate goal of advancing treatment efficacy, accessibility, and patient outcomes.

Radiotherapy in cervical cancer treatment

Cervical cancer ranks among the most prevalent and life-threatening malignancies affecting women worldwide. Its impact on mortality and quality of life necessitates comprehensive and effective treatment strategies. Radiotherapy has emerged as a cornerstone in the management of cervical cancer due to its ability to target tumor cells with precision while minimizing harm to surrounding healthy tissues [13].

Historically, conventional radiotherapy techniques, including external beam radiotherapy and brachytherapy, have been the primary modalities for treating cervical cancer. External beam radiotherapy delivers controlled doses of radiation to the tumor from outside the body, while brachytherapy involves placing radioactive sources directly into or near the tumor [14]. These techniques have demonstrated success in tumor control but often come with challenges such as radiation toxicity, treatment duration, and recurrence risks. The steep dose gradient between the tumor and surrounding tissues can lead to toxicity in nearby organs, affecting patients' quality of life. Moreover, the reliance on anatomical landmarks for treatment planning may result in variations in dose delivery and suboptimal tumor control.

Innovative Radiotherapy interventions

Recent years have seen a tremendous change in the field of radiation, fueled by technological advancements and a growing comprehension of cancer biology. With more accurate, efficient, and customized treatment options available, innovative radiation interventions have become a ray of hope for cancer patients [15]. With the least amount of harm to the surrounding healthy tissues, these innovative techniques target tumors with previously unheard-of accuracy thanks to the use of cutting-edge Imaging, software, and delivery systems some of which are listed in Table 1.

Tab. 1. Radiobiological Mechanisms of Action in Innovative Radiotherapy Interventions in Cervical Cancer Treatment

S. No.	INTERVENTIONS	Mechanism of Action	Advantages	Challenges	Radiobiological Advantages	References
1.	Intensity-Modulated Radiation Therapy (IMRT)	Delivering radiation doses precisely while protecting healthy tissues, slowed down DNA repair procedures	Reduced toxicities and improved tumor control	Cost, required technology, and experience	Improved tumor control and increased DNA damage	(Lee et al., 2023; Sminia et al.,2023)
2.	Image-Guided Radiotherapy (IGRT)	Radiation delivery and real-time imaging	Improved treatment precision and fewer failures	Expertise needed for equipment handling.	Improves the consistency of dosages given to patients,	(Dawson et al.,2006; Barbera et al.,2023)
3.	Proton Beam Therapy	Concentration of energy in the tumor	Less deterioration of the adjacent healthy tissues	Expensive and accessibility constraints	Lower radiation damage due to concentrated energy in the tumor	(Taunk et al.,2022;Yanazume et al.,2015; Mayani et al.,2015)
4.	Combination Therapies	Combined effects of chemotherapy and immunotherapy	Enhanced disease management and survival results	Integration issues and consequences	Improvements in tumor response, disease control, and survival	(Zugazagoitia et al.,2016; Drake et al., 2016)

Intensity-Modulated Radiation Therapy (IMRT)

IMRT is a cutting-edge technique that enables the delivery of radiation with varying intensities, allowing for precise targeting of tumor volumes while sparing adjacent healthy tissues. This approach minimizes radiation-related toxicities and enhances local control. 83 patients with stage IB-IVA cervical cancer were treated in the worldwide multicentre randomized phase II INTERTECC trial with concomitant weekly cisplatin and IMRT [16]. In this experiment, the efficacy of PET-based IG-IMRT was also investigated, and it was discovered that patients receiving IG-IMRT had a considerably decreased incidence of acute grade 3 neutropenia. Using a simultaneous integrated boost strategy, doses to the main tumor and substantially affected lymph nodes can be increased relative to selected nodal areas. This technique has been demonstrated to be well tolerated and to have encouraging control rates [17]. Volumetric intensity-modulated arc radiation treatment (VMAT) uses arcs to administer IMRT rather than using numerous static fields. With a recent meta-analysis of dosimetric studies favouring VMAT about the rectum V40 (the irradiation volume of the rectum getting 40 Gy), it is clear that VMAT has several benefits, including quicker treatment times and fewer monitor units [18]. With IMRT, the doctor can set dosage requirements for both the target. These needs can subsequently be assigned various relative priorities throughout the dose optimization process.

Image-Guided Radiotherapy (IGRT)

IGRT combines imaging techniques such as CT scans and MRI with real-time radiation delivery, ensuring accurate tumor targeting even when anatomical structures shift due to physiological changes. This technology minimizes errors and enhances treatment accuracy. IGRT's real-time imaging capabilities have translated into improved treatment accuracy and patient outcomes. A prospective study by (Johnson et al. (2018)) revealed that IGRT led to a reduction in treatment errors and improved overall response rates [19]. The ability to adapt treatment plans based on anatomical changes contributed to increased tumor control rates and reduced recurrence risks.

Proton beam therapy

Proton therapy offers a more targeted approach than traditional photon-based radiation, reducing damage to healthy tissues surrounding the tumor. Its ability to spare normal tissues is particularly beneficial in cervical cancer treatment. Due to the distinctive Bragg peak of proton treatment, which shows a quick dose fall-off distal to the target depth, it is dosimetrically superior to photon-based EBRT. Numerous dosimetric investigations, particularly in the lower dosage zones, have revealed possible dose reductions to normal organs [20-22]. The pelvic bone marrow, bladder, and intestine received lower volumes of 10 to 30 Gy according to the proton programs. Grade 2 and 3 haematological toxicities were present in 33% and 11% of the nine individuals receiving concurrent treatment. The practicality and dosimetric benefits were demonstrated by the fact that just one patient had grade 3 acute gastrointestinal toxicity and no patients encountered grade 3 genitourinary toxicity. With early dosimetric data suggesting the feasibility of sparing one ovary to a mean dose of 15 Gy while maintaining dose to

target volumes with intensity-modulated proton therapy, improved ovarian sparing to preserve endocrine function in women needing whole pelvis EBRT is another possible benefit of proton therapy [20]. However, proton-based prospective comparative clinical studies are sparse, and it is still unknown to what extent dosimetric advancements transfer into therapeutic benefits for patients.

Combination therapies

Presently, chemotherapy complements

definitive loco-regional treatments (such as surgery or radiotherapy) in cervical cancer patients to enhance their prognosis, and it also serves as a palliative measure for those with recurrent or newly developed metastatic disease [23].

The integration of radiotherapy with chemotherapy, immunotherapy, or targeted agents shows promise in enhancing treatment efficacy. Concurrent chemoradiotherapy, for instance, has improved survival outcomes by addressing local and systemic diseases [24].

Numerous studies have showcased the potential of innovative radiotherapy interventions in improving survival rates and reducing treatment-related side effects some of them are listed in Table 2. IMRT has exhibited superior tumor control and reduced toxicities compared to conventional techniques. Proton therapy has demonstrated excellent outcomes in reducing toxicity to nearby organs. The combination of radiotherapy with chemotherapy or immunotherapy has led to better disease management and survival rates.

Innovative radiotherapy interventions present a paradigm shift in the landscape of cervical cancer treatment. The evolution from traditional techniques to more advanced modalities has led to improved tumor control, reduced toxicities, and enhanced patient outcomes [25]. As the field continues to progress, these interventions hold the promise of further enhancing cervical cancer survival rates and patient quality of life, underscoring the importance of their continued research, development, and integration into clinical practice.

Tab. 2. Clinical Trials of Innovative Radiotherapy Interventions

Trial Name	Phase	Sample Size	Interventions	Primary outcomes	References
INTERTECC-2 [1]	Phase II	83 Patients	Cisplatin + IMRTTumor control	toxicity	[1] (Mell et al., 2017)
PARCER [2]	Phase III	350 Patients	IG-IMRT + chemotherapy	Progression-free survival, toxicity	[2] (hopra et al.,2021)
Proton Therapy Study [3]	Phase II	60 patients	Proton therapy + Chemotherapy	Local control, quality of life	[3] (ryant et al., 2016)
VMAT vs. IMRT [4]	Phase I	45 patients	VMAT vs. IMRT	Dosimetric comparisons	[4] (Deng et al.,2018)
Combination Therapy [5]	Phase II	150 patients	Radiotherapy + Immunotherapy	Overall survival, toxicity	[5] (Ratto et al., 2000)
RTOG 1203 [6]	Phase III	550 patients	Chemoradiotherapy image-guided brachytherapy	Disease-free survival toxicity	[6] (Rose et al., 2019)
ProCERV Trial [7]	Phase II	120 patients	Proton therapy + chemotherapy	Overall response rate, quality of life	[7] (in et al., 2020)
IGRT with IMRT with VMAT [8]	Phase III	30 patients	Adaptive IGRT/VMAT + chemotherapy	Treatment response, toxicity	[8] (urekha et al., 2017)
Hypofractionation Trial [9]	Phase II	200 patients	Hypofractionated IMRT + cisplatin	Local control, acute toxicity	[9] (Mallick et al., 2018)
Immunoradiotherapy [10]	Phase II	80 patients	IG-IMRT + immunotherapy	Progression-free survival, toxicity	[10] (Huynh et al., 2022)

MOSES in PARCER [11]	Phase III	300 patients	3DCRT vs IMRT	Toxicity	[11] (Ranjan et al.22)
STARS [12]	Phase III	1048 women patients	CCRT+RT	SCRT may be a more effective treatment approach	[12] (Huang et al.,2021)

Benefits and challenges of innovative interventions

In the pursuit of enhancing treatment outcomes for cervical cancer, innovative interventions have garnered attention. These approaches, including IMRT, Image-Guided Radiotherapy (IGRT), and proton beam therapy, offer precision in targeting tumor tissues while minimizing damage to healthy structures. As a result, patients experience reduced treatment-related complications, translating into an improved quality of life during and after treatment [26]. Additionally, combining radiotherapy with modalities such as chemotherapy and immunotherapy provides a multimodal approach that addresses local and systemic disease, potentially leading to more comprehensive disease management and prolonged survival. Furthermore, these innovative interventions enable the tailoring of treatment plans to individual patient characteristics, promoting a patient-centric approach to cervical cancer management and presenting promising prospects for improved outcomes in the field.

Challenges of innovative interventions

Advanced interventions like proton therapy and IMRT require specialized equipment and expertise, which often necessitate substantial technological and infrastructural investments, posing significant challenges in resource-limited settings.

While these innovative treatments offer substantial benefits, their accessibility tends to be restricted to select medical centres, exacerbating healthcare disparities, particularly in regions with limited resources.

Moreover, despite promising initial outcomes, the long-term efficacy and potential late effects of these interventions necessitate extensive follow-up data, presenting an ongoing challenge. Additionally, the involvement of complex procedures and cutting-edge technologies in innovative interventions may result in higher treatment costs, requiring careful consideration in healthcare decision-making. Furthermore, the intricate nature of some interventions demands meticulous treatment planning, underscoring the importance of specialized training for radiation oncologists and physicists. While the advantages of integrating these innovative interventions into cervical cancer treatment are evident in their potential to enhance precision, tumor control, and minimize complications, addressing these challenges through collaborative efforts among healthcare professionals, researchers, policymakers, and technology developers is essential for their equitable and effective integration into cervical cancer care.

Clinical evidence corroborates the potential of innovative interventions to significantly elevate cervical cancer survival rates. Techniques such as IMRT, IGRT, proton therapy, and combination therapies consistently exhibit superior tumor control, decreased treatment-related adverse effects, and an overall enhancement in patient outcomes. The assimilation of these interventions into clinical practice can redefine the treatment landscape, providing renewed optimism and improved prognostic prospects for individuals battling cervical cancer. Furthermore, the synergy between radiotherapy and immunotherapy offers promise for a paradigm shift in cervical cancer treatment [27]. Notably, a study by illustrates that the amalgamation of radiotherapy with immune checkpoint inhibitors augments anti-tumor immune responses, resulting in extended disease control and heightened survival rates. This potential for enduring remissions and sustained responses signifies a noteworthy advancement in the care of cervical cancer patients.

Radiobiology and mechanisms of action

Radiobiology serves as the cornerstone for comprehending the mechanisms through which pioneering interventions in cervical cancer treatment exert their influence. The precision of IMRT, the energy deposition capabilities of proton therapy, and the synergistic effects of combination therapies all collectively contribute to heightened DNA damage and superior tumor control. By harnessing these radiobiological principles, these interventions present an innovative avenue for advancing the outcomes of cervical cancer treatment. A profound grasp of the radiobiology and mechanisms of action underpinning these ground breaking approaches is imperative for optimizing their effectiveness. This section delves into the intricate interactions between these interventions and tumor cells, their impact on DNA damage, and the resultant enhancements in treatment outcomes.

Mechanisms of action for innovative interventions

To precisely shape radiation beams and provide very accurate dose distributions that are suited to the tumor's spatial dimensions, IMRT uses complex computer algorithms. This accuracy reduces the chance of treatment-related negative effects by delivering stronger radiation doses inside the tumor while progressively

lowering radiation exposure to nearby healthy tissues. Contrarily, proton treatment makes use of the special physical characteristics of protons, which concentrate their energy largely within the tumor tissue, sparing nearby healthy tissues from needless radiation doses as a result of the Bragg peak phenomenon. This strategy considerably lowers the danger of radiation therapy-related side effects.

Enhanced DNA damage and tumor control

Advanced radiation treatments like IMRT and proton therapy excel in administering precise radiation doses that improve the vulnerability of tumor cells to DNA damage while minimizing exposure to normal tissues, reducing treatment-related problems. These treatments make use of radiobiological advantages by delaying the DNA repair processes of tumor cells, making it more difficult for them to recover from radiation-induced damage, and eventually increasing therapy efficacy. Additionally, IMRT and proton therapy successfully treat hypoxic areas, overcoming the limitations of the Oxygen Enhancement Ratio (OER), which gauges the efficiency of radiation in the presence of oxygen. These cutting-edge therapies exhibit not just technological development but also draw power from fundamental radiobiological principles, resulting in higher rates of tumor control.

FUTURE DIRECTIONS AND IMPLICATIONS

Emerging technologies (Bradley 2006; WHO 2013) offer alternative approaches to current screening and precancer treatment methods, potentially facilitating more efficient targeting of women at risk [28]. These technologies encompass HPV DNA testing, RNA-protein testing, visual inspection with acetic acid (VIA), high-resolution micro-endoscopy, handheld digital colposcopy, and other innovative solutions [29].

Technology breakthroughs, individualized treatment plans, combination medicines, and patient-centred care will alter cervical cancer treatment in the future with the incorporation of novel radiation methods. Real-time treatment precision is promised by cutting-edge imaging techniques like MRI-guided radiation, and particle treatments like proton therapy have the potential to be improved and made more widely available. Personalized treatment regimens based on biomarkers and dosimetric optimization will enhance results, and the interaction of targeted medicines with radiation and immunotherapy may result in long-lasting remissions. While efforts worldwide are made to adapt these interventions in resource-limited contexts and analyse their cost-effectiveness to address healthcare inequities and inform decision-making, patient-centric care strives to shorten treatment times and improve quality of life. But also improved life quality and equitable access to care for cervical cancer patients.

CONCLUSION

Advanced radiation techniques, encompassing IMRT, IGRT, and proton therapy, present an opportunity for enhanced tumor control and reduced treatment side effects, ultimately leading to improved patient outcomes. These precision-based therapies represent a paradigm shift in the management of cervical cancer. However, while the path toward optimal cervical cancer treatment is promising, challenges persist. To ensure that the benefits of these innovative treatments are accessible to all patients, addressing disparities in treatment access, cost considerations, and the necessity for long-term data validation requires collaborative efforts. The integration of personalized treatment plans, combination therapies, and cutting-edge technology holds great promise for the future of cervical cancer treatment. As the field evolves, its impact extends beyond survival rates to encompass improvements in quality of life, cost-effective treatment approaches, and equitable access to advanced therapies. Advancements in technology, tailored treatment plans, and international healthcare policies collectively pave the way for a brighter future for cervical cancer patients. This comprehensive study serves as a roadmap, emphasizing the ongoing need for research, collaboration, and the integration of novel radiation therapies to enhance cervical cancer survival and elevate the overall standard of care.

REFERENCES

1. Ferlay J, Ervik M, Lam F. Global cancer observatory: Cancer today. Fr Int Agency Res Cancer Retrieved. 2021.
2. Krings A, Dunyo P, Pesic A, Tetteh S, Hansen B, et al. Characterization of Human Papillomavirus prevalence and risk factors to guide cervical cancer screening in the North Tongu District, Ghana. PLoS One. 2019; 14(6):0218762.
3. Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8(2):191-203.
4. Blackstone EC, Daly BJ. The Need for Specialized Oncology Training for Clinical Ethicists. InHEC Forum 2022.
5. Chino J, Annunziata CM, Beriwal S, Bradfield L, Erickson BA, et al. Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline. Pract radiat oncol. 2020; 10(4):220-34.
6. Small Jr W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, et al. Cervical cancer: a global health crisis. Cancer. 2017; 123(13):2404-12.
7. Fleischmann M, Chatzikonstantinou G, Fokas E, Wichmann J, Christiansen H, et al. Molecular markers to predict prognosis and treatment response in uterine cervical cancer. Cancers. 2021; 13(22):5748.
8. Yang H, Jin T, Li M, Xue J, Lu B. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precis Clin Med.2019; 2(1):57-70.
9. Rosenblatt E, Izewska J, Anacak Y, Pynda Y, Scalliet P, et al. Radiotherapy capacity in European countries: an analysis of the Directory of Radiotherapy Centres (DIRAC) database. lancet oncol.2013; 14(2):79-86.
10. Kaur P, Mantha, A. K., Sharma, A, Bakshi, N, Kumar, R. Radiation Therapy and Immune Response: The Unexplored Link in Cervical Cancer. Frontiers in Oncology, 12, 795773.2022
11. Potter R, Georg P, Dimopoulos JC, Grimm M, Berger D, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol.2011; 100(1):116-23.
12. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, et al. Cancer and inflammation: promise for biological therapy. J. immunother. 2010; 33(4):335.
13. Citrin DE. Recent developments in radiotherapy. N. Engl j med. 2017; 377(11):1065-75.
14. Rijkmans EC, Nout RA, Rutten IH, Ketelaars M, Neelis KJ, et al. Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol oncol.2014; 135(2):231-38.
15. Elbanna M, Pynda Y, Kalinchuk O, Rosa A, Abdel-Wahab M. Radiotherapy resources in Latin America and the Caribbean: a review of current and projected needs based on International Atomic Energy Agency data. Lancet Oncol. 2023; 24(9):376-84.
16. Mell LK, Sirak I, Wei L, Tarnawski R, Mahantshetty U, et al. Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. 2017; 97(3):536-45.
17. Jethwa KR, Jang S, Gonuguntla K, Evans JD, Block MS, et al. Lymph node-directed simultaneous integrated boost in patients with clinically lymph node-positive cervical cancer treated with definitive chemoradiation: clinical outcomes and toxicity. Int. J. Radiat Oncol Biol Phys. 2018. 102(3):625-26.
18. Bai W, Kou C, Yu W, Li Y, Hua W, et al. Dosimetric comparison of volumetric-modulated arc therapy and intensity-modulated radiation therapy in patients with cervical cancer: a meta-analysis. OncoTargets ther. 2018: 7179-86.
19. Johnson-Hart CN, Price GJ, Faivre-Finn C, Aznar MC, van Herk M. Residual setup errors towards the heart after image guidance linked with poorer survival in lung cancer patients: do we need stricter IGRT protocols?. Int. J. Radiat. Oncol. Biol. Phys. 2018 O; 102(2):434-42.
20. Vyfhuis MA, Fellows Z, McGovern N, Zhu M, Mohindra P, et al. Preserving endocrine function in premenopausal women undergoing whole pelvis radiation for cervical cancer. Int j part. ther. 2019; 6(1):10-17.
21. Dinges E, Felderman N, McGuire S, Gross B, Bhatia S, et al. Bone marrow sparing in intensity modulated proton therapy for cervical cancer: Efficacy and robustness under range and setup uncertainties.Radiother. Oncol.. 2015; 115(3):373-78.
22. Marnitz S, Wlodarczyk W, Neumann O, Koehler, C, Weihrauch, et al. Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation–an intraindividual comparison. Radiother. Oncol. 2015. 10(1): 1-9.
23. Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA, Bamias A. Systemic therapy in cervical cancer: 30 years in review. Crit. rev oncol hematol.. 2019; 137:9-17.
24. Martin OA, Anderson RL, Narayan K, MacManus MP. Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?. Nat. rev. Clin. oncol. 2017; 14(1):32-44.
25. Girma B, Makonnen E, Shibeshi W. Characteristics of recent clinical investigations into systemic therapy against cervical cancer: systematic analysis of trial details from Clinicaltrials. gov. J. Obstet. Gynaecol. 2022; 42(5):793-801.
26. Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. InSeminars in Radiation Oncology 2013.
27. Hashimoto S, Shibamoto Y, Iwata H, Ogino H, Shibata H, et al. Whole-pelvic radiotherapy with spot-scanning proton beams for uterine cervical cancer: a planning study. J. Radiat. Res.2016; 57(5):524-32.
28. Bradley J, Coffey P, Arrossi S, Agurto I, Bingham A, et al. Women's perspectives on cervical screening and treatment in developing countries: experiences with new technologies and service delivery strategies. Women health. 2006; 43(3):103-21.
29. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. 2013.